← All trials
NCT01135212
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2010
- Primary completion
- Apr 1, 2011
- Completion date
- May 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 290
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- KuyngPook National HospitalOverall official - principal investigator
- Inje UniversityCollaborator
- Daegu Catholic UniversityCollaborator
- Kosin UniversityCollaborator
- Keimyung UniversityCollaborator
- Yeungnam UniversityCollaborator
- Dong-A PharmaceuticalCollaborator
- Gyeongsang UniversityCollaborator
- Kyungpook UniversityCollaborator
- University of UlsanCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.